Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 18484 entries
Sorted by: Best Match Show Resources per page
Modulation of lethal and persistent rat parvovirus infection by antibody.

Archives of virology

Gaertner DJ, Jacoby RO, Paturzo FX, Johnson EA, Brandsma JL, Smith AL.
PMID: 1646590
Arch Virol. 1991;118(1):1-9. doi: 10.1007/BF01311299.
Free PMC Article

Two day-old athymic (rnu/rnu) and euthymic (rnu/+) rat pups nursing immune or non-immune dams were inoculated oronasally with the Yale strain of rat virus (RV-Y). All athymic and euthymic pups (57/57) from immune dams remained clinically normal, whereas 51...

Cite
Gaertner DJ, Jacoby RO, Paturzo FX, et al. Modulation of lethal and persistent rat parvovirus infection by antibody. Arch Virol. 1991;118(1):1-9doi: 10.1007/BF01311299.
Gaertner, D. J., Jacoby, R. O., Paturzo, F. X., Johnson, E. A., Brandsma, J. L., & Smith, A. L. (1991). Modulation of lethal and persistent rat parvovirus infection by antibody. Archives of virology, 118(1), 1-9. https://doi.org/10.1007/BF01311299
Gaertner, D J, et al. "Modulation of lethal and persistent rat parvovirus infection by antibody." Archives of virology vol. 118,1 (1991): 1-9. doi: https://doi.org/10.1007/BF01311299
Gaertner DJ, Jacoby RO, Paturzo FX, Johnson EA, Brandsma JL, Smith AL. Modulation of lethal and persistent rat parvovirus infection by antibody. Arch Virol. 1991;118(1):1-9. doi: 10.1007/BF01311299. PMID: 1646590; PMCID: PMC7086996.
Copy Download .nbib Format: NLM
A prospective trial of prophylactic intravenous immune globulin for the prevention of infections in severely burned patients.

Burns : journal of the International Society for Burn Injuries

Waymack JP, Jenkins ME, Alexander JW, Warden GD, Miller AC, Carey M, Ogle CK, Kopcha RG.
PMID: 2500137
Burns. 1989 Apr;15(2):71-6. doi: 10.1016/0305-4179(89)90132-0.

A prospective randomized double-blind study evaluated the efficacy of i.v. immune globulin in preventing infectious complications in severely burned patients. Fifty patients were randomized to receive either i.v. immune globulin or placebo. Each group of patients was treated with...

Cite
Waymack JP, Jenkins ME, Alexander JW, et al. A prospective trial of prophylactic intravenous immune globulin for the prevention of infections in severely burned patients. Burns. 1989;15(2):71-6doi: 10.1016/0305-4179(89)90132-0.
Waymack, J. P., Jenkins, M. E., Alexander, J. W., Warden, G. D., Miller, A. C., Carey, M., Ogle, C. K., & Kopcha, R. G. (1989). A prospective trial of prophylactic intravenous immune globulin for the prevention of infections in severely burned patients. Burns : journal of the International Society for Burn Injuries, 15(2), 71-6. https://doi.org/10.1016/0305-4179(89)90132-0
Waymack, J P, et al. "A prospective trial of prophylactic intravenous immune globulin for the prevention of infections in severely burned patients." Burns : journal of the International Society for Burn Injuries vol. 15,2 (1989): 71-6. doi: https://doi.org/10.1016/0305-4179(89)90132-0
Waymack JP, Jenkins ME, Alexander JW, Warden GD, Miller AC, Carey M, Ogle CK, Kopcha RG. A prospective trial of prophylactic intravenous immune globulin for the prevention of infections in severely burned patients. Burns. 1989 Apr;15(2):71-6. doi: 10.1016/0305-4179(89)90132-0. PMID: 2500137.
Copy Download .nbib Format: NLM
[Clinical experiences of LAK therapy in patients with hepatocellular carcinoma].

Journal of UOEH

Zeki K, Sakamoto H, Okuno F, Sujita K, Eto S.
PMID: 2554458
J UOEH. 1989 Sep 01;11(3):341-5. doi: 10.7888/juoeh.11.341.

A patient with hepatocellular carcinoma (HCC) was treated with newly established adoptive immunotherapy using LAK cells (LAK therapy) together with transcatheter arterial embolization therapy (TAE). This patient responded well, and the therapeutic efficacy still continues 6 months after the...

Cite
Zeki K, Sakamoto H, Okuno F, et al. [Clinical experiences of LAK therapy in patients with hepatocellular carcinoma]. J UOEH. 1989;11(3):341-5doi: 10.7888/juoeh.11.341.
Zeki, K., Sakamoto, H., Okuno, F., Sujita, K., & Eto, S. (1989). [Clinical experiences of LAK therapy in patients with hepatocellular carcinoma]. Journal of UOEH, 11(3), 341-5. https://doi.org/10.7888/juoeh.11.341
Zeki, K, et al. "[Clinical experiences of LAK therapy in patients with hepatocellular carcinoma]." Journal of UOEH vol. 11,3 (1989): 341-5. doi: https://doi.org/10.7888/juoeh.11.341
Zeki K, Sakamoto H, Okuno F, Sujita K, Eto S. [Clinical experiences of LAK therapy in patients with hepatocellular carcinoma]. J UOEH. 1989 Sep 01;11(3):341-5. doi: 10.7888/juoeh.11.341. Japanese. PMID: 2554458.
Copy Download .nbib Format: NLM
The role of mucus in antibody-mediated rapid expulsion of Trichinella spiralis in suckling rats.

Immunology

Carlisle MS, McGregor DD, Appleton JA.
PMID: 2354857
Immunology. 1990 May;70(1):126-32.

Rat pups suckling dams parasitized by Trichinella spiralis express rapid expulsion, a protective response that is associated with the entrapment of infectious muscle larvae in intestinal mucus. Immunofluorescent studies revealed that antibodies were bound to the surfaces of the...

Cite
Carlisle MS, McGregor DD, Appleton JA. The role of mucus in antibody-mediated rapid expulsion of Trichinella spiralis in suckling rats. Immunology. 1990;70(1):126-32
Carlisle, M. S., McGregor, D. D., & Appleton, J. A. (1990). The role of mucus in antibody-mediated rapid expulsion of Trichinella spiralis in suckling rats. Immunology, 70(1), 126-32.
Carlisle, M S, et al. "The role of mucus in antibody-mediated rapid expulsion of Trichinella spiralis in suckling rats." Immunology vol. 70,1 (1990): 126-32.
Carlisle MS, McGregor DD, Appleton JA. The role of mucus in antibody-mediated rapid expulsion of Trichinella spiralis in suckling rats. Immunology. 1990 May;70(1):126-32. PMID: 2354857; PMCID: PMC1384093.
Copy Download .nbib Format: NLM
Mechanisms of resistance to autoimmune disease induced by T-cell vaccination.

Autoimmunity

Lohse AW, Cohen IR.
PMID: 1932518
Autoimmunity. 1991;9(2):119-21. doi: 10.3109/08916939109006747.

No abstract available.

Cite
Lohse AW, Cohen IR. Mechanisms of resistance to autoimmune disease induced by T-cell vaccination. Autoimmunity. 1991;9(2):119-21doi: 10.3109/08916939109006747.
Lohse, A. W., & Cohen, I. R. (1991). Mechanisms of resistance to autoimmune disease induced by T-cell vaccination. Autoimmunity, 9(2), 119-21. https://doi.org/10.3109/08916939109006747
Lohse, A W, and Cohen, I R. "Mechanisms of resistance to autoimmune disease induced by T-cell vaccination." Autoimmunity vol. 9,2 (1991): 119-21. doi: https://doi.org/10.3109/08916939109006747
Lohse AW, Cohen IR. Mechanisms of resistance to autoimmune disease induced by T-cell vaccination. Autoimmunity. 1991;9(2):119-21. doi: 10.3109/08916939109006747. PMID: 1932518.
Copy Download .nbib Format: NLM
Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.

Journal of immunology (Baltimore, Md. : 1950)

Shu S, Rosenberg SA.
PMID: 2411817
J Immunol. 1985 Oct;135(4):2895-903.

A newly induced syngeneic transplantable sarcoma, MCA 105, was used for studies of the biologic characteristics of fresh noncultured and secondarily in vitro sensitized (IVS) cells with antitumor reactivity. Fresh spleen cells harvested from mice immunized to the MCA...

Cite
Shu S, Rosenberg SA. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells. J Immunol. 1985;135(4):2895-903
Shu, S., & Rosenberg, S. A. (1985). Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells. Journal of immunology (Baltimore, Md. : 1950), 135(4), 2895-903.
Shu, S, and Rosenberg, S A. "Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells." Journal of immunology (Baltimore, Md. : 1950) vol. 135,4 (1985): 2895-903.
Shu S, Rosenberg SA. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells. J Immunol. 1985 Oct;135(4):2895-903. PMID: 2411817.
Copy Download .nbib Format: NLM
Immunologic mechanisms and target antigens in testicular autoimmunity.

Annals of the New York Academy of Sciences

Tung KS, Mahi-Brown CA, Yule TD.
PMID: 2528312
Ann N Y Acad Sci. 1989;564:267-80. doi: 10.1111/j.1749-6632.1989.tb25904.x.

No abstract available.

Cite
Tung KS, Mahi-Brown CA, Yule TD. Immunologic mechanisms and target antigens in testicular autoimmunity. Ann N Y Acad Sci. 1989;564:267-80doi: 10.1111/j.1749-6632.1989.tb25904.x.
Tung, K. S., Mahi-Brown, C. A., & Yule, T. D. (1989). Immunologic mechanisms and target antigens in testicular autoimmunity. Annals of the New York Academy of Sciences, 564267-80. https://doi.org/10.1111/j.1749-6632.1989.tb25904.x
Tung, K S, et al. "Immunologic mechanisms and target antigens in testicular autoimmunity." Annals of the New York Academy of Sciences vol. 564 (1989): 267-80. doi: https://doi.org/10.1111/j.1749-6632.1989.tb25904.x
Tung KS, Mahi-Brown CA, Yule TD. Immunologic mechanisms and target antigens in testicular autoimmunity. Ann N Y Acad Sci. 1989;564:267-80. doi: 10.1111/j.1749-6632.1989.tb25904.x. PMID: 2528312.
Copy Download .nbib Format: NLM
Seroconversion for hepatitis C virus antibody in bone marrow recipients treated with immune globulin.

The New England journal of medicine

Horst HA, Schmitz N, Glinike C, Löffler H, Laufs R.
PMID: 1646961
N Engl J Med. 1991 Jul 11;325(2):132-3. doi: 10.1056/NEJM199107113250214.

No abstract available.

Cite
Horst HA, Schmitz N, Glinike C, et al. Seroconversion for hepatitis C virus antibody in bone marrow recipients treated with immune globulin. N Engl J Med. 1991;325(2):132-3doi: 10.1056/NEJM199107113250214.
Horst, H. A., Schmitz, N., Glinike, C., Löffler, H., & Laufs, R. (1991). Seroconversion for hepatitis C virus antibody in bone marrow recipients treated with immune globulin. The New England journal of medicine, 325(2), 132-3. https://doi.org/10.1056/NEJM199107113250214
Horst, H A, et al. "Seroconversion for hepatitis C virus antibody in bone marrow recipients treated with immune globulin." The New England journal of medicine vol. 325,2 (1991): 132-3. doi: https://doi.org/10.1056/NEJM199107113250214
Horst HA, Schmitz N, Glinike C, Löffler H, Laufs R. Seroconversion for hepatitis C virus antibody in bone marrow recipients treated with immune globulin. N Engl J Med. 1991 Jul 11;325(2):132-3. doi: 10.1056/NEJM199107113250214. PMID: 1646961.
Copy Download .nbib Format: NLM
An immunoprotective monoclonal antibody directed against Leptospira interrogans serovar copenhageni.

Journal of general microbiology

Schoone GJ, Everard CO, Korver H, Carrington DG, Inniss VA, Baulu J, Terpstra WJ.
PMID: 2778433
J Gen Microbiol. 1989 Jan;135(1):73-8. doi: 10.1099/00221287-135-1-73.

A monoclonal antibody (mAb) was prepared by hybridoma technology in BALB/c mice immunized to Leptospira interrogans serovar copenhageni. This mAb agglutinated serovars copenhageni and icterohaemorrhagiae to high titres and protected hamsters, dogs and monkeys against challenge with a virulent...

Cite
Schoone GJ, Everard CO, Korver H, et al. An immunoprotective monoclonal antibody directed against Leptospira interrogans serovar copenhageni. J Gen Microbiol. 1989;135(1):73-8doi: 10.1099/00221287-135-1-73.
Schoone, G. J., Everard, C. O., Korver, H., Carrington, D. G., Inniss, V. A., Baulu, J., & Terpstra, W. J. (1989). An immunoprotective monoclonal antibody directed against Leptospira interrogans serovar copenhageni. Journal of general microbiology, 135(1), 73-8. https://doi.org/10.1099/00221287-135-1-73
Schoone, G J, et al. "An immunoprotective monoclonal antibody directed against Leptospira interrogans serovar copenhageni." Journal of general microbiology vol. 135,1 (1989): 73-8. doi: https://doi.org/10.1099/00221287-135-1-73
Schoone GJ, Everard CO, Korver H, Carrington DG, Inniss VA, Baulu J, Terpstra WJ. An immunoprotective monoclonal antibody directed against Leptospira interrogans serovar copenhageni. J Gen Microbiol. 1989 Jan;135(1):73-8. doi: 10.1099/00221287-135-1-73. PMID: 2778433.
Copy Download .nbib Format: NLM
Kawasaki disease. Epidemiology, late prognosis, and therapy.

Rheumatic diseases clinics of North America

Barron KS.
PMID: 1767080
Rheum Dis Clin North Am. 1991 Nov;17(4):907-19.

Kawasaki disease is an immunologically mediated diffuse vasculitis of childhood of unknown etiology. While most of the clinical features--including diffuse mucosal inflammation, indurative edema, rash, and lymphadenopathy--are self-limiting, coronary artery aneurysms and the possibility of thrombotic occlusion occurs in...

Cite
Barron KS. Kawasaki disease. Epidemiology, late prognosis, and therapy. Rheum Dis Clin North Am. 1991;17(4):907-19
Barron, K. S. (1991). Kawasaki disease. Epidemiology, late prognosis, and therapy. Rheumatic diseases clinics of North America, 17(4), 907-19.
Barron, K S. "Kawasaki disease. Epidemiology, late prognosis, and therapy." Rheumatic diseases clinics of North America vol. 17,4 (1991): 907-19.
Barron KS. Kawasaki disease. Epidemiology, late prognosis, and therapy. Rheum Dis Clin North Am. 1991 Nov;17(4):907-19. PMID: 1767080.
Copy Download .nbib Format: NLM
Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy and in neuropathy associated with IgM monoclonal gammopathy of unknown significance.

Neurology

Dyck PJ.
PMID: 2300259
Neurology. 1990 Feb;40(2):327-8. doi: 10.1212/wnl.40.2.327.

No abstract available.

Cite
Dyck PJ. Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy and in neuropathy associated with IgM monoclonal gammopathy of unknown significance. Neurology. 1990;40(2):327-8doi: 10.1212/wnl.40.2.327.
Dyck, P. J. (1990). Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy and in neuropathy associated with IgM monoclonal gammopathy of unknown significance. Neurology, 40(2), 327-8. https://doi.org/10.1212/wnl.40.2.327
Dyck, P J. "Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy and in neuropathy associated with IgM monoclonal gammopathy of unknown significance." Neurology vol. 40,2 (1990): 327-8. doi: https://doi.org/10.1212/wnl.40.2.327
Dyck PJ. Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy and in neuropathy associated with IgM monoclonal gammopathy of unknown significance. Neurology. 1990 Feb;40(2):327-8. doi: 10.1212/wnl.40.2.327. PMID: 2300259.
Copy Download .nbib Format: NLM
The uses of intravenous immune globulin in collagen vascular disorders.

The Journal of allergy and clinical immunology

Ballow M, Parke A.
PMID: 2529304
J Allergy Clin Immunol. 1989 Oct;84(4):608-12. doi: 10.1016/0091-6749(89)90198-x.

Studies in our laboratory demonstrated that the long-term administration of intravenous immune serum globulin in patients with common variable hypogammaglobulinemia produced increased suppressor activity, which resulted in diminished in vitro B cell immunoglobulin synthesis. These studies suggested that intravenous...

Cite
Ballow M, Parke A. The uses of intravenous immune globulin in collagen vascular disorders. J Allergy Clin Immunol. 1989;84(4):608-12doi: 10.1016/0091-6749(89)90198-x.
Ballow, M., & Parke, A. (1989). The uses of intravenous immune globulin in collagen vascular disorders. The Journal of allergy and clinical immunology, 84(4), 608-12. https://doi.org/10.1016/0091-6749(89)90198-x
Ballow, M, and Parke, A. "The uses of intravenous immune globulin in collagen vascular disorders." The Journal of allergy and clinical immunology vol. 84,4 (1989): 608-12. doi: https://doi.org/10.1016/0091-6749(89)90198-x
Ballow M, Parke A. The uses of intravenous immune globulin in collagen vascular disorders. J Allergy Clin Immunol. 1989 Oct;84(4):608-12. doi: 10.1016/0091-6749(89)90198-x. PMID: 2529304.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 18484 entries